PMID: 15373992Sep 18, 2004Paper

Treatment of patients with ventricular preexcitation

Revista española de cardiología
Jesús Almendral GarroteAngel Arenal Maiz

Abstract

Ventricular preexcitation, due to an accessory pathway that creates an electrical connection between the atria with the ventricles, can provide a substrate for a variety of arrhythmogenic syndromes, from paroxysmal AV junctional tachycardia, to the facilitation or aggravation of atrial tachyarrhythmias that can lead to sudden death. However, statistics show that the most frequent situation is for the individual to remain asymptomatic throughout his or her life. In the asymptomatic individual, population-based studies with very long follow-up periods indicate that the risk of sudden death is minimal. Acute therapy for tachyarrhythmias is based on adenosine/verapamil for regular, narrow-QRS tachycardias and procainamide/electrical cardioversion for preexcited tachyarrhythmias. Chronic pharmacologic therapy with antiarrhythmic drugs is not recommended because its efficacy is not well proven and its risk of side effects can be considerable. In symptomatic patients, the treatment of choice is catheter ablation, with an efficacy of 93%, a complication rate of 1% and a mortality rate of 1 per thousand. Whether catheter ablation should be recommended for asymptomatic individuals remains controversial. The authors recommend that these i...Continue Reading

References

Nov 15, 1979·The New England Journal of Medicine·G J KleinJ J Gallagher
Dec 5, 1991·The New England Journal of Medicine·A J Camm, C J Garratt
Mar 1, 1990·Journal of the American College of Cardiology·K J BeckmanR J Hariman
Apr 1, 1990·International Journal of Cardiology·I VassiliadisC Stefanadis
Mar 1, 1989·Pacing and Clinical Electrophysiology : PACE·M SatohA Shibata
Aug 1, 1995·Pacing and Clinical Electrophysiology : PACE·M M Scheinman
Apr 1, 1993·European Heart Journal·B Brembilla-Perrot, R Ghawi
Nov 7, 2003·The New England Journal of Medicine·Carlo PapponeSalvatore Rosanio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Arrhythmogenic Right Ventricular Dysplasia

Arrhythmogenic right ventricular dysplasia is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the right ventricle wall and loss of myocardial cells. Primary injuries usually are at the free wall of the right ventricular and right atria resulting in ventricular and supraventricular arrhythmias. Discover the latest research on arrhythmogenic right ventricular dysplasia here.